Cargando…

Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy

Major challenges for cancer treatment are how to effectively eliminate primary tumor and sufficiently induce immunogenic cell death (ICD) to provoke a robust immune response for metastasis control. Here, a self-assembled cascade bioreactor was developed to improve cancer treatment with enhanced tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Hao, Yong, Jiahui, Yang, Qingqing, Yang, Zhen, Liu, Zhangya, Xu, Yan, Wang, Hao, Jiang, Xing, Miao, Wenjun, Li, Xueming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546854/
https://www.ncbi.nlm.nih.gov/pubmed/34729313
http://dx.doi.org/10.1016/j.apsb.2021.05.005
_version_ 1784590274278719488
author Ren, Hao
Yong, Jiahui
Yang, Qingqing
Yang, Zhen
Liu, Zhangya
Xu, Yan
Wang, Hao
Jiang, Xing
Miao, Wenjun
Li, Xueming
author_facet Ren, Hao
Yong, Jiahui
Yang, Qingqing
Yang, Zhen
Liu, Zhangya
Xu, Yan
Wang, Hao
Jiang, Xing
Miao, Wenjun
Li, Xueming
author_sort Ren, Hao
collection PubMed
description Major challenges for cancer treatment are how to effectively eliminate primary tumor and sufficiently induce immunogenic cell death (ICD) to provoke a robust immune response for metastasis control. Here, a self-assembled cascade bioreactor was developed to improve cancer treatment with enhanced tumor penetration and synergistic therapy of starvation, chemodynamic (CDT) and photothermal therapy. Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction. After accumulated at tumor sites, FGP disassembles to smaller FeS-GOx for enhanced deep tumor penetration. GOx maintains high enzymatic activity to catalyze glucose with assistant of oxygen to generate hydrogen peroxide (H(2)O(2)) as starvation therapy. Fenton reaction involving the regenerated H(2)O(2) in turn produced more hydroxyl radicals for enhanced CDT. Following near-infrared laser at 808 nm, FGPs displayed pronounced tumor inhibition in vitro and in vivo by the combination therapy. The consequent increased exposure to calreticulin amplified ICD and promoted dendritic cells maturation. In combination with anti-CTLA4 checkpoint blockade, FGP can absolutely eliminate primary tumor and avidly inhibit distant tumors due to the enhanced intratumoral infiltration of cytotoxic T lymphocytes. Our work presents a promising strategy for primary tumor and metastasis inhibition.
format Online
Article
Text
id pubmed-8546854
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85468542021-11-01 Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy Ren, Hao Yong, Jiahui Yang, Qingqing Yang, Zhen Liu, Zhangya Xu, Yan Wang, Hao Jiang, Xing Miao, Wenjun Li, Xueming Acta Pharm Sin B Original Article Major challenges for cancer treatment are how to effectively eliminate primary tumor and sufficiently induce immunogenic cell death (ICD) to provoke a robust immune response for metastasis control. Here, a self-assembled cascade bioreactor was developed to improve cancer treatment with enhanced tumor penetration and synergistic therapy of starvation, chemodynamic (CDT) and photothermal therapy. Ultrasmall FeS-GOx nanodots were synthesized with glucose oxidase (GOx) as template and induced by paclitaxel (PTX) to form self-assembling FeS-GOx@PTX (FGP) via hydrophobic interaction. After accumulated at tumor sites, FGP disassembles to smaller FeS-GOx for enhanced deep tumor penetration. GOx maintains high enzymatic activity to catalyze glucose with assistant of oxygen to generate hydrogen peroxide (H(2)O(2)) as starvation therapy. Fenton reaction involving the regenerated H(2)O(2) in turn produced more hydroxyl radicals for enhanced CDT. Following near-infrared laser at 808 nm, FGPs displayed pronounced tumor inhibition in vitro and in vivo by the combination therapy. The consequent increased exposure to calreticulin amplified ICD and promoted dendritic cells maturation. In combination with anti-CTLA4 checkpoint blockade, FGP can absolutely eliminate primary tumor and avidly inhibit distant tumors due to the enhanced intratumoral infiltration of cytotoxic T lymphocytes. Our work presents a promising strategy for primary tumor and metastasis inhibition. Elsevier 2021-10 2021-05-13 /pmc/articles/PMC8546854/ /pubmed/34729313 http://dx.doi.org/10.1016/j.apsb.2021.05.005 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ren, Hao
Yong, Jiahui
Yang, Qingqing
Yang, Zhen
Liu, Zhangya
Xu, Yan
Wang, Hao
Jiang, Xing
Miao, Wenjun
Li, Xueming
Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
title Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
title_full Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
title_fullStr Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
title_full_unstemmed Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
title_short Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
title_sort self-assembled fes-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546854/
https://www.ncbi.nlm.nih.gov/pubmed/34729313
http://dx.doi.org/10.1016/j.apsb.2021.05.005
work_keys_str_mv AT renhao selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT yongjiahui selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT yangqingqing selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT yangzhen selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT liuzhangya selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT xuyan selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT wanghao selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT jiangxing selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT miaowenjun selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy
AT lixueming selfassembledfesbasedcascadebioreactorwithenhancedtumorpenetrationandsynergistictreatmentstotriggerrobustcancerimmunotherapy